Cargando…

Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study

Background: Efforts in reproductive preservation for cancer patients have become one of the important aspects of cancer management. In fact, decline in reproductive function is known to occur after exposure to anti-cancer treatments. Measuring anti-Müllerian hormone (AMH) levels is known to be the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Harzif, Achmad Kemal, Wiweko, Budi, Addina, Putri, Iswaranti, Kartika, Silvia, Melisa, Mariana, Ana, Mutia, Kresna, Sumapraja, Kanadi, Muharam, R, Pratama, Gita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059784/
https://www.ncbi.nlm.nih.gov/pubmed/32185016
http://dx.doi.org/10.12688/f1000research.15728.3
_version_ 1783504119138353152
author Harzif, Achmad Kemal
Wiweko, Budi
Addina, Putri
Iswaranti, Kartika
Silvia, Melisa
Mariana, Ana
Mutia, Kresna
Sumapraja, Kanadi
Muharam, R
Pratama, Gita
author_facet Harzif, Achmad Kemal
Wiweko, Budi
Addina, Putri
Iswaranti, Kartika
Silvia, Melisa
Mariana, Ana
Mutia, Kresna
Sumapraja, Kanadi
Muharam, R
Pratama, Gita
author_sort Harzif, Achmad Kemal
collection PubMed
description Background: Efforts in reproductive preservation for cancer patients have become one of the important aspects of cancer management. In fact, decline in reproductive function is known to occur after exposure to anti-cancer treatments. Measuring anti-Müllerian hormone (AMH) levels is known to be the best parameter in predicting ovarian reserves, which indicates reproductive function. In total, 68% of cancer survivors of reproductive age who underwent anti-cancer treatments suffer from infertility. Meanwhile, ovarian reserves also decrease with increasing age. There is ongoing debate on whether the ovarian reserves of cancer patients could be reduced long before exposure to anti-cancer therapy. Therefore, it is important to know whether ovarian reserves in cancer patients decrease before or after anti-cancer therapy. This can help predict the reproductive function in such cases and the effectiveness of ovarian preservation efforts. Methods: A cross-sectional study was conducted, comparing the AMH levels of 44 female cancer patients of reproductive age before cancer therapy, to 44 non-cancer patients of reproductive age (age matched) . The AMH was determined from blood.The biological ages from both groups were adjusted using the Indonesian Kalkulator of Oocytes. Results: The median age in both groups was 28 years old. The AMH levels in the blood of the cancer group were found to be significantly lower in contrast to those in the non-cancer group (1.11 [0.08-4.65] ng/ml vs. 3.99 [1.19- 8.7]; p- value <0.001). Therefore, the biological age in the cancer group was 10 years older than that of the non-cancer group, indicating that ovarian aging occurs earlier in cancer patients. Conclusions: AMH levels of cancer patients of reproductive age were already reduced before cancer therapy, given an older biological age, in contrast to that of the non-cancer patients. Proper counseling and implementation of fertility-preserving methods is highly recommended in this group of patients.
format Online
Article
Text
id pubmed-7059784
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-70597842020-03-16 Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study Harzif, Achmad Kemal Wiweko, Budi Addina, Putri Iswaranti, Kartika Silvia, Melisa Mariana, Ana Mutia, Kresna Sumapraja, Kanadi Muharam, R Pratama, Gita F1000Res Research Article Background: Efforts in reproductive preservation for cancer patients have become one of the important aspects of cancer management. In fact, decline in reproductive function is known to occur after exposure to anti-cancer treatments. Measuring anti-Müllerian hormone (AMH) levels is known to be the best parameter in predicting ovarian reserves, which indicates reproductive function. In total, 68% of cancer survivors of reproductive age who underwent anti-cancer treatments suffer from infertility. Meanwhile, ovarian reserves also decrease with increasing age. There is ongoing debate on whether the ovarian reserves of cancer patients could be reduced long before exposure to anti-cancer therapy. Therefore, it is important to know whether ovarian reserves in cancer patients decrease before or after anti-cancer therapy. This can help predict the reproductive function in such cases and the effectiveness of ovarian preservation efforts. Methods: A cross-sectional study was conducted, comparing the AMH levels of 44 female cancer patients of reproductive age before cancer therapy, to 44 non-cancer patients of reproductive age (age matched) . The AMH was determined from blood.The biological ages from both groups were adjusted using the Indonesian Kalkulator of Oocytes. Results: The median age in both groups was 28 years old. The AMH levels in the blood of the cancer group were found to be significantly lower in contrast to those in the non-cancer group (1.11 [0.08-4.65] ng/ml vs. 3.99 [1.19- 8.7]; p- value <0.001). Therefore, the biological age in the cancer group was 10 years older than that of the non-cancer group, indicating that ovarian aging occurs earlier in cancer patients. Conclusions: AMH levels of cancer patients of reproductive age were already reduced before cancer therapy, given an older biological age, in contrast to that of the non-cancer patients. Proper counseling and implementation of fertility-preserving methods is highly recommended in this group of patients. F1000 Research Limited 2020-02-20 /pmc/articles/PMC7059784/ /pubmed/32185016 http://dx.doi.org/10.12688/f1000research.15728.3 Text en Copyright: © 2020 Harzif AK et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Harzif, Achmad Kemal
Wiweko, Budi
Addina, Putri
Iswaranti, Kartika
Silvia, Melisa
Mariana, Ana
Mutia, Kresna
Sumapraja, Kanadi
Muharam, R
Pratama, Gita
Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study
title Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study
title_full Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study
title_fullStr Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study
title_full_unstemmed Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study
title_short Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study
title_sort anti-mullerian hormone levels in female cancer patients of reproductive age in indonesia: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059784/
https://www.ncbi.nlm.nih.gov/pubmed/32185016
http://dx.doi.org/10.12688/f1000research.15728.3
work_keys_str_mv AT harzifachmadkemal antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT wiwekobudi antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT addinaputri antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT iswarantikartika antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT silviamelisa antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT marianaana antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT mutiakresna antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT sumaprajakanadi antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT muharamr antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy
AT pratamagita antimullerianhormonelevelsinfemalecancerpatientsofreproductiveageinindonesiaacrosssectionalstudy